ASML’s EUV Monopoly Powers the Global AI Chip Boom 
Trump Administration Takes Stake in USA Rare Earth to Boost U.S. Critical Minerals Supply 
Hyundai Motor Shares Slide After Trump Signals Higher U.S. Tariffs on South Korean Goods 
Tesla Loses Ground in Europe as BYD Accelerates EV Market Share in 2025 
Embraer Targets Growth as Regional Jet Demand Surges Post-Pandemic 
Ford and GM Near Financing Deal to Support First Brands Group During Bankruptcy 
Delta Air Lines Operates Reduced Flight Schedule as Winter Storm Disrupts U.S. Travel 
ANTA Sports to Acquire Major Stake in Puma in €1.5 Billion Deal, Signaling Strategic Revival 
Samsung Set to Begin HBM4 Production for Nvidia and AMD 
Microsoft Wins Approval to Build 15 New Data Centers in Wisconsin 
Baker Hughes Reports 11% Rise in Q4 Adjusted Profit Driven by LNG Demand 
Micron to Expand Memory Chip Manufacturing Capacity in Singapore Amid Global Shortage 
BYD and Exxon Mobil Strengthen Hybrid Technology Partnership 
UK Politicians Call for Full Competition Review of Netflix’s Warner Bros Discovery Deal 
Noble Corporation Secures $1.3 Billion in New Contracts, Strengthening Offshore Drilling Backlog 
NEWARK, Calif., May 16, 2017 -- Depomed, Inc. (NASDAQ:DEPO) today announced that members of senior management will participate in a fireside chat at the 2017 UBS Global Healthcare Conference scheduled for 10:00 am ET (7:00 am PT) on Tuesday, May 23, 2017 in New York, New York.
This presentation will be webcast and can be accessed via the Investor Relations page of the Depomed website at www.depomed.com. A recording of the webcasts will be archived for 30 days.
About Depomed
Depomed is a leading specialty pharmaceutical company focused on enhancing the lives of the patients, families, physicians, providers and payors we serve through commercializing innovative products for pain and neurology related disorders. Depomed markets six medicines with areas of focus that include mild to severe acute pain, moderate to severe chronic pain, neuropathic pain, migraine and breakthrough cancer pain. Depomed is headquartered in Newark, California. To learn more about Depomed, visit www.depomed.com.
Investor Contact: Christopher Keenan VP, Investor Relations and Corporate Communications 510-744-8000 [email protected]
